Clinical Trial

A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke

Study acronym: ACT-IVATE
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
Trial Details
NCT Number NCT07742098
Lead Sponsor NeuroTrauma Sciences, LLC
Conditions Acute Ischemic Stroke
Enrollment 140 participants
Start Date 2026-10-31
Primary Completion 2028-12-15 (estimated)
Study Completion 2028-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-03